TransMedics Group, Inc. Payments to Acquire Marketable Securities
TransMedics Group, Inc. (TMDX) reported Payments to Acquire Marketable Securities of $10.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-02-27
- TransMedics Group, Inc. payments to acquire marketable securities for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- TransMedics Group, Inc. payments to acquire marketable securities for the quarter ending 2022-09-30 was $988.00K, a 95.35% decline year-over-year.
- TransMedics Group, Inc. payments to acquire marketable securities for the quarter ending 2022-06-30 was $7.47M, a 77.85% decline year-over-year.
- TransMedics Group, Inc. payments to acquire marketable securities for the quarter ending 2022-03-31 was $2.03M, a 82.64% decline year-over-year.
- TransMedics Group, Inc. payments to acquire marketable securities for fiscal 2022 was $10.50M, a 85.43% decline from fiscal 2021.
- TransMedics Group, Inc. payments to acquire marketable securities for fiscal 2021 was $72.02M, a 40.86% decline from fiscal 2020.
- TransMedics Group, Inc. payments to acquire marketable securities for fiscal 2020 was $121.79M, a 47.86% increase from fiscal 2019.
- TransMedics Group, Inc. payments to acquire marketable securities for fiscal 2019 was $82.37M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $988.00K derived: sum of 2 quarters · filed 2025-02-27 | $8.46M derived: sum of 3 quarters · filed 2025-02-27 | $10.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | $988.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $8.46M derived: sum of 2 quarters · filed 2023-11-08 | $10.50M 10-Q · filed 2023-11-08 | $15.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $7.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $9.51M 10-Q · filed 2023-08-04 | $14.84M derived: sum of 3 quarters · filed 2024-02-27 | $36.07M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $2.03M 10-Q · filed 2023-05-04 | $7.36M derived: sum of 2 quarters · filed 2024-02-27 | $28.60M derived: sum of 3 quarters · filed 2024-02-27 | $62.35M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $26.56M derived: sum of 2 quarters · filed 2024-02-27 | $60.32M derived: sum of 3 quarters · filed 2024-02-27 | $72.02M 10-K · filed 2024-02-27 |
| 2021-09-30 | $21.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $54.99M derived: sum of 2 quarters · filed 2022-11-04 | $66.69M 10-Q · filed 2022-11-04 | $86.97M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $33.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $45.46M 10-Q · filed 2022-08-03 | $65.74M derived: sum of 3 quarters · filed 2023-02-27 | $103.62M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $11.71M 10-Q · filed 2022-05-05 | $31.99M derived: sum of 2 quarters · filed 2023-02-27 | $69.86M derived: sum of 3 quarters · filed 2023-02-27 | $129.33M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $20.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $58.16M derived: sum of 2 quarters · filed 2023-02-27 | $117.63M derived: sum of 3 quarters · filed 2023-02-27 | $121.79M 10-K · filed 2023-02-27 |
| 2020-09-30 | $37.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $97.34M derived: sum of 2 quarters · filed 2021-11-09 | $101.51M 10-Q · filed 2021-11-09 | $116.21M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $59.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $63.64M 10-Q · filed 2021-08-06 | $78.33M derived: sum of 3 quarters · filed 2021-05-07 | $97.06M derived: sum of 4 quarters · filed 2021-05-07 |
| 2020-03-31 | $4.17M 10-Q · filed 2021-05-07 | $18.86M derived: sum of 2 quarters · filed 2021-05-07 | $37.59M derived: sum of 3 quarters · filed 2021-05-07 | |
| 2019-12-28 | $14.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $33.43M derived: sum of 2 quarters · filed 2021-03-11 | $82.37M 10-K · filed 2021-03-11 | |
| 2019-09-28 | $18.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $67.68M 10-Q · filed 2019-11-08 | ||
| 2019-06-29 | $48.95M 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |